(Reuters) -Drugmaker AstraZeneca lifted its annual sales and ... The new investments will expand manufacturing sites in Maryland, Texas and California and create 1,000 high-skilled jobs in the ...
The new investments will expand manufacturing sites in Maryland, Texas and California. But AstraZeneca shares have fallen nearly 6% this year, underperforming a near 9% rise in the wider European ...
AstraZeneca made headlines for several reasons on Tuesday ... The investment will also support creation of a new next generation manufacturing facility, focused on biologics, in Maryland as well as ...
Outside of Massachusetts, AstraZeneca said its expanding U.S. footprint includes a manufacturing facility for biologics in Maryland, cell therapy manufacturing capacity on the West and East Coasts ...
Cambridge, England-based biopharmaceutical giant AstraZeneca is pouring billions ... a next-generation biologics manufacturing facility in Maryland, specialty manufacturing in Texas and cell ...
The pact with Mankind Pharma, announced in March 2024, was an exclusive agreement for distribution of budesonide and ...
AstraZeneca’s expanding footprint in the US includes, among others: A state-of-the-art R&D centre in Kendall Square, Cambridge, Massachusetts; A next generation manufacturing facility for biologics in ...
AstraZeneca has upgraded its annual guidance ... centre in Massachusetts and a manufacturing facility for biologics in Maryland. Soriot said the investment reflects the 'attractiveness of the ...
Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong ...